PDX1-positive foregut endoderm cell enrichment via segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating insulin-producing β-cells from human embryonic stem cells (hESCs) are inefficient, requiring large quantities of scarce islet cells and facing challenges in directed differentiation due to the pluripotency of hESCs, which leads to low efficiency and variability in cell type production.
Innovation Solution
The development of compositions and methods to produce and enrich PDX1-positive foregut endoderm cells, which can differentiate into pancreatic islet/β-cells, involving the use of retinoid compounds, FGF-10, B27, and activin A/B to promote differentiation and increase PDX1 expression, allowing for the isolation and purification of these cells using markers like HOXA13 and HOXC6.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If human embryonic stem cells are used for generating insulin-producing β-cells, then the source of starting material is abundant and pluripotent, but the differentiation efficiency is low and cell type production is variable
Solution Approach 1:
The patent segments the differentiation process into distinct stages by introducing intermediate cell types (definitive endoderm, foregut endoderm, pancreatic endoderm) as measurable milestones. This segmentation allows for controlled progression through the differentiation pathway, improving overall efficiency from pluripotent stem cells to insulin-producing β-cells.
Solution Approach 2:
The patent employs preliminary actions by first generating definitive endoderm cells before proceeding to foregut endoderm and pancreatic endoderm. This staged approach with preliminary intermediate steps ensures proper lineage commitment and enhances the reliability of final β-cell production.
2Quantity of substance
If large quantities of islet cells are required for cell therapy, then sufficient material for transplant can be obtained, but the scarcity of donor pancreases limits availability
Solution Approach 1:
The patent enables self-service by using human embryonic stem cells as an autonomous source that can be cultured and differentiated in vitro to produce sufficient quantities of islet cells. This eliminates dependence on scarce donor pancreases, as the stem cell system self-generates the required cell quantities through controlled differentiation.
Solution Approach 2:
The patent performs preliminary generation and expansion of stem cell populations before differentiation into islet cells. This preliminary expansion step ensures sufficient starting material is available to produce the large quantities of islet cells needed for therapy, bypassing the limitation of donor organ scarcity.
3Measurement precision
If intermediate cell types are isolated and characterized, then appropriate lineage precursors can be identified, but the complexity of the differentiation pathway increases
Solution Approach 1:
The patent segments the complex differentiation pathway into distinct, characterizable intermediate stages (definitive endoderm, foregut endoderm, pancreatic endoderm). Each segment has identifiable markers and characteristics, allowing precise measurement and control while managing overall pathway complexity through systematic division.
Solution Approach 2:
The patent introduces intermediate cell types as mediators between pluripotent stem cells and final islet cells. These intermediary stages serve as controlled transition points that facilitate the complex differentiation process, making it manageable through sequential, characterizable steps.
Data Source
AI summary
Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.